Xilio Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
XLO$8.53-5.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
CONSOLIDATED STATEMENTS OF
STOCKHOLDERS’ EQUITY
(In thousands, except share data)
| Additional · Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Accumulated · Stockholders’ | |||||||||
| Shares · Amount · Capital · Deficit · Equity | |||||||||
| Balance at December 31, 2023 | 1,971,974 | $ | — | $ | 362,339 | $ | (325,512) | $ | 36,827 |
| Issuance of common stock and prefunded warrants to Gilead and certain accredited investors in private placements, net of issuance costs | 789,896 | — | 25,680 | — | 25,680 | ||||
| Issuance of common stock in connection with at-the-market offerings, net of issuance costs | 500,000 | — | 6,825 | — | 6,825 | ||||
| Issuance of common stock under employee stock purchase plan | 5,423 | — | 68 | — | 68 | ||||
| Vesting of restricted common stock | 398 | — | — | — | — | ||||
| Exercise of stock options | 608 | — | 5 | — | 5 | ||||
| Stock-based compensation expense | — | — | 6,434 | — | 6,434 | ||||
| Net loss | — | — | — | (58,241) | (58,241) | ||||
| Balance at December 31, 2024 | 3,268,299 | $ | — | $ | 401,351 | $ | (383,753) | $ | 17,598 |
| Issuance of prefunded warrants in connection with a follow-on offering, net of issuance costs | — | — | 10,818 | — | 10,818 | ||||
| Issuance of common stock in connection with the exercise of prefunded warrants | 524,033 | — | 1 | — | 1 | ||||
| Issuance of common stock and prefunded warrants in connection with the exercise of Series B warrants, net of issuance costs | 300,200 | — | 26,945 | — | 26,945 | ||||
| Conversion of Series B common stock warrant liabilities to equity | — | — | 3,095 | — | 3,095 | ||||
| Issuance of common stock in connection with the AbbVie stock purchase agreement, net of issuance costs | 310,559 | — | 2,810 | — | 2,810 | ||||
| Issuance of common stock in connection with at-the-market offerings, net of issuance costs | 110,747 | — | 2,017 | — | 2,017 | ||||
| Issuance of common stock under employee stock purchase plan | 7,508 | — | 76 | — | 76 | ||||
| Vesting of restricted common stock | 7,952 | — | — | — | — | ||||
| Exercise of stock options | 1,343 | — | 10 | — | 10 | ||||
| Stock-based compensation expense | — | — | 6,939 | — | 6,939 | ||||
| Net loss | — | — | — | (35,036) | (35,036) | ||||
| Balance at December 31, 2025 | 4,530,641 | $ | — | $ | 454,062 | $ | (418,789) | $ | 35,273 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.